



# EVIDENCE FOR THE USE OF INNOVATIVE RADIATION TECHNIQUES FOR BREAST CANCER

---

**Authors** *(in alphabetical order):*

**Alex De Caluwé**, Institut Jules Bordet

**Katrien Erven**, Iridium Kankernetwerk

**Carine Kirkove**, Cliniques Universitaires Saint-Luc

**Vincent Remouchamps**, CHU UCL Namur

**Liv Veldeman**, UZ Gent

**Caroline Weltens**, UZ Leuven



# TABLE OF CONTENTS

---

3	ABOUT BRAVO
4	BENEFIT OF BREAST RADIOTHERAPY
5	SIDE EFFECTS
6	TECHNIQUES TO REDUCE TOXICITY: IMRT / VMAT / HELICAL TOMOTHERAPY HYPOFRACTIONATION PARTIAL BREAST IRRADIATION PRONE POSITION RESPIRATION RELATED TECHNIQUES
9	REFERENCES
11	LIST OF ABBREVIATIONS / DEFINITIONS

# ABOUT BRAVO

---

BRAVO is the **B**elgian **R**adiation **O**ncology **A**wareness and **V**isibility **O**rganization. Radiation oncology is a medical treatment specialty mainly used to treat cancer and related diseases. It is important to differentiate radiation oncology from radiology, medical imaging, nuclear medicine, chemotherapy and nuclear power production.

The Belgian radiation oncology providers (physicians, medical physicist, nursing staff) team up with the medical industry that offers the tools and systems to provide high quality radiation therapy treatments to patients with cancer. The medical and industrial partners within BRAVO decided to create better awareness of radiation-oncology as a very safe and very modern treatment method of cancer. The main aim of this cooperation is to spread this message among patients, medical colleagues, politicians and press.

BeMedTech, the Belgian federation for the industry of medical technologies, serves as the umbrella for BRAVO.

BRAVO cooperates closely with BVRO-ABRO, the Belgian Association for Radiotherapy-Oncology.

# BENEFIT OF BREAST RADIOOTHERAPY

---

Curative treatment for breast cancer consists of surgery, radiotherapy and systemic treatments such as chemotherapy, antihormonal therapy and targeted agents. The local treatment options are breast conserving treatment, consisting of breast sparing surgery followed by radiotherapy, and mastectomy with or without radiotherapy. Radiotherapy is used to eradicate occult microscopic disease in the breast, the chest wall and the draining regional nodal areas and has shown to decrease local recurrence rates and to improve survival with an absolute gain in breast cancer mortality of 8,1% at 20 years<sup>1</sup>. Those improved outcomes compare favourably to systemic chemotherapy as studied by the same group and methodology (6,5% absolute 10 y gain for anthracyclines, with an additional 2,8% gain at 8 years for taxane delivery)<sup>2</sup>. Hormonal treatment is associated with a 10,6% 15 year gain in breast cancer mortality<sup>3</sup>.

The randomized studies from the 1970 -1980s usually delivered the radiation dose locally (breast or chest wall) and to the regional nodes<sup>1</sup>. The concept of stopping metastases at their source was understood<sup>4</sup>.

In 2015, 3 major studies were published and demonstrated the additional value of nodal directed radiation, in addition to breast and post-mastectomy chest wall fields: the randomized trials EORTC 22922 trial<sup>5</sup> and NCIC MA 20<sup>6</sup> demonstrated a significant gain in metastases-free survival and breast cancer mortality, while a Danish population based cohort study demonstrated an improved overall survival with internal mammary irradiation<sup>7</sup>. The recent AMAROS study<sup>8</sup> suggests that after a positive sentinel node procedure, additional surgical clearance can sometimes safely be replaced by nodal irradiation.

Breast cancer is nowadays a highly curable disease that affects a large proportion of the Belgian population. High quality treatment should therefore not only focus on disease eradication but also on the quality of life of the long-term survivors. The introduction of innovative radiotherapy technology allows not only to improve the dose delivery to the target volumes, but also to better spare the normal tissues adjacent to the target volumes. For breast cancer patients this means that doses to the heart, lungs, oesophagus, thyroid and contralateral breast can be decreased substantially. The aim of the present paper is to describe how these new radiotherapy techniques can have an effect on normal tissue complication probabilities.

# SIDE EFFECTS

---

Acute skin toxicity and impaired long-term cosmesis are well-known side effects of breast radiotherapy. In the acute phase dermatitis, moist desquamation, oedema and pain have been described<sup>9</sup>. Late breast toxicities include suboptimal cosmesis, breast shrinkage, telangiectasia, induration (fibrosis), oedema and pigmentation<sup>10</sup>. Both acute breast toxicity (in particular moist desquamation) and breast cosmesis have an impact on quality of life<sup>9,11</sup>.

Pericarditis is the typical acute manifestation of radiation injury to the heart, while coronary artery disease, cardiomyopathy and valvular disease are possible late complications<sup>12</sup>. In the past, the heart was thought to be relatively radioresistant to the effects of radiation and damaged only by doses of  $\geq 30$  Gy. More recent data from several independent sources have provided substantial evidence that the mean heart dose of  $\leq 20$  Gy and even  $\leq 5$  Gy can increase the risk<sup>13</sup>. Darby et al. investigated the occurrence of major coronary events in 2168 women who underwent radiotherapy for breast cancer between 1958 and 2001<sup>14</sup>. They found that the rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per Gray, with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy.

Breast radiotherapy is also associated with an increased risk of radiation-induced pneumonitis, lung fibrosis and secondary lung cancer<sup>15-17</sup>. A prospective cohort study of more than 500,000 women in the US SEER cancer database showed a lung cancer mortality ratio in irradiated women, ipsilateral (irradiated side) versus contralateral (non-irradiated side), of 1.30<sup>18</sup>. This ratio increases with time since diagnosis of breast cancer, with no significant excess during the first 10 years. More than 20 years after diagnosis, the mortality ratio, ipsilateral versus contralateral, peaks to 3.87. The risk of developing a secondary lung cancer increases linearly per Gy extra lung dose<sup>19,20</sup>. For smokers the excess risk is significantly higher than for non-smokers<sup>19</sup>.

# TECHNIQUES TO REDUCE TOXICITY:

---

## IMRT / VMAT / HELICAL TOMOTHERAPY

Intensity modulated radiation therapy or IMRT is a technique in which the beams are subdivided in smaller beams of varying intensities to precisely irradiate the tumour. In breast radiotherapy the most common form of IMRT is based on 2 opposing beams, usually referred to as 'field-in-field IMRT'. For more complex targets, multiple beams are used, often referred to as 'full IMRT'. An alternative for full IMRT is VMAT (Volumetric Modulated Arc Therapy) or Helical Tomotherapy (HT).

Field-in-field IMRT allows to compensate for the complex 3D shape of the breast leading to an increased dose homogeneity in the breast and a decrease of the areas receiving excessive dose (hot spots) compared to 3D conformal radiotherapy (3D CRT). Several studies have demonstrated that IMRT therefore reduces the incidence of acute dermatitis, oedema, and hyperpigmentation. Less skin telangiectasia and improved cosmesis were also demonstrated<sup>9,10,21</sup>.

Dosimetric studies confirm that full IMRT, VMAT and HT also provide excellent target coverage, improved dose homogeneity and conformity in the target volumes and reduced high doses to organs at risk (OAR) compared to 3D CRT<sup>22-24</sup>. However, in the same time these techniques often give low doses to larger volumes of normal tissues such as the contralateral breast, the lungs and the heart<sup>25-27</sup>. Nevertheless, the risk to benefit ratio seems to be in favour of these techniques as opposed to 3D CRT in complex target volumes, such as funnel chest, tumour in the inner quadrant when internal mammary chain and tumour bed boost are indicated, large breast size, bilateral breast irradiation, patients with implants or unfavourable cardiac anatomy<sup>24-26,28,29</sup>.

## HYPOFRACTIONATION

Hypofractionation, in which a larger dose of radiation is delivered with each treatment, thereby reducing the total number of treatment days and the total dose, has been evaluated in several trials comparing 13 to 16 daily treatments to conventionally fractionated radiation, consisting of 25 daily treatments. Three large and recent randomised trials with 10-year follow up results are available<sup>30,31</sup>. With long-term follow-up, these studies have found equivalent rates of local/locoregional control and survival with similar or improved toxicity and cosmetic outcomes in favour of the hypo fractionated schedule.

In START-A moderate or marked breast induration, telangiectasia and breast oedema were significantly less common in the 39 Gy regimen patients group than in the 50 Gy regimen group. Moderate or marked normal tissue effects did not differ significantly between 41.6 Gy and 50 Gy (1).

In START-B moderate or marked breast shrinkage, telangiectasia and breast oedema were significantly lower with 40 Gy than with 50 Gy respectively 26,2% vs 31,2% (p:0.015), 4,2% vs 5,8% (p: 0.032) and 5,1% vs 9% (p:0.001) (1). In the Canadian study, at 10 years no significant differences in global cosmetic outcome were observed between the groups at any time.

## PARTIAL BREAST IRRADIATION

Partial breast irradiation (PBI), in which only the part of the breast where the tumour was removed – and not the whole breast – is irradiated, offers the benefit of sparing healthy tissue because a considerably smaller breast volume is irradiated. Patient Reported Outcomes Measures (PROM) from the IMPORT-LOW trial using IMRT revealed significantly less change in breast appearance in the PBI group<sup>33</sup> and interstitial brachytherapy lead to fewer grade 2–3 late skin side-effects<sup>34</sup>. Intra-operative radiotherapy (IORT) reduces overall skin side effects in comparison to WBI, particularly erythema, dryness, hyper-pigmentation and pruritus<sup>35</sup>. In comparison to WBI, PBI with IMRT can greatly reduce the radiation dose to the heart due to the ability of limiting the extension of the posterior field border and thus removing the heart from the treatment fields. In a case of left-sided breast cancer that is not located in the vicinity of the heart, the breast tissue close to the heart that would be irradiated with WBI can be excluded from the target volume. Interstitial Brachytherapy is less effective in reducing the heart dose than PBI with IMRT, but the heart dose can be lowered in comparison to WBI depending on the tumour location.

In a meta-analysis of 8 randomized trials comparing PBI with WBI, a higher rate of local recurrences was observed in the PBI group<sup>36</sup>. However, some studies indicate that PBI with IMRT or multicatheter interstitial brachytherapy might be as effective as WBI in terms of controlling local recurrences if the technique is restricted to rigorously selected patients<sup>33,34,37</sup>. These trials have, however, a limited follow-up of maximum 5 years.

## PRONE POSITION

The prone position for whole-breast irradiation was first described in literature for large-breasted patients, who are at a higher risk of developing skin toxicity. In prone position, the breast hangs down through an aperture and due to gravity the breast becomes narrower and skin folds disappear, resulting in better dose homogeneity, less overdosages and less dose to the skin. This translates in improved acute skin toxicity and breast cosmesis as shown in a randomized trial comparing prone and supine breast irradiation<sup>38,39</sup>. Long-term outcome data are not yet available for prone breast irradiation. The New York University School of Medicine reports excellent locoregional control after a very limited follow-up of 5 years in 404 patients<sup>40</sup>.

In prone position, the breast falls away from the intrathoracic organs by gravity. This translates in a reduced radiation dose to the lungs in whole-breast irradiation. Evidence in literature is very consistent: prone is superior to supine position for sparing of lung tissue and this in all patients regardless of breast size or other anatomical features<sup>38,41-43</sup>.

Prone position is also an effective means of reducing heart dose compared to supine position in about 85% of patients<sup>43</sup>. In the remaining 15%, mostly small breasted females, there is a risk of increased radiation dose to the heart in prone position<sup>41,43</sup>. The latter problem might be solved by using respiration related techniques, which are also feasible in prone position<sup>44</sup>. Drawbacks of prone breast irradiation are the uncomfortable and complicated positioning procedure which is sometimes difficult to reproduce.

## RESPIRATION RELATED TECHNIQUES

Breathing-adapted radiation techniques can be engaged to take advantage of the respiratory motion by irradiating only in deep inspiration. In this respiratory phase, the heart moves inferiorly and posteriorly, enlarging the distance between the breast target volume and the heart. Studies examining the dosimetric benefit of breathing-adapted radiation techniques for breast cancer patients have shown a clear reduction in cardiac doses<sup>28,32</sup>. A variety of strategies exist to perform breathing-adapted radiotherapy. For breast cancer patients, deep inspiration breath-hold (DIBH) techniques, free breathing respiratory-gated techniques or DIBH respiratory-gated techniques are used.

# REFERENCES

---

1. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* 2014;383:2127-35.
2. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet* 2012;379:432-44.
3. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. *Lancet* 2011;378:771-84.
4. Hellman S. Stopping metastases at their source. *N Engl J Med* 1997;337:996-7.
5. Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. *N Engl J Med* 2015;373:317-27.
6. Whelan TJ, Olivetto IA, Parulekar WR, et al. Regional Nodal Irradiation in Early-Stage Breast Cancer. *N Engl J Med* 2015;373:307-16.
7. Thorsen LB, Offersen BV, Dano H, et al. DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. *J Clin Oncol* 2015;34:314-20.
8. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol* 2014;15:1303-10.
9. Pignol JP, Olivetto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol* 2008;26:2085-92.
10. Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. *J Clin Oncol* 2013;31:4488-95.
11. Hau E, Browne L, Capp A, et al. The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial. *Breast Cancer Res Treat* 2013;139:115-23.
12. Taunk NK, Haffty BG, Kostis JB, Goyal S. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. *Front Oncol* 2015;5:39.
13. Kingsley P, Negi P. Radiation induced cardiotoxicity in left sided breast cancer - Where do we stand? *Health Res* 2015; 2:8-13.
14. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013;368:987-98.
15. Kahan Z, Csenki M, Varga Z, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients. *Int J Radiat Oncol Biol Phys* 2007;68:673-81.
16. Nishioka A, Ogawa Y, Hamada N, Terashima M, Inomata T, Yoshida S. Analysis of radiation pneumonitis and radiation-induced lung fibrosis in breast cancer patients after breast conservation treatment. *Oncol Rep* 1999;6:513-7.
17. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;366:2087-106.
18. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer* 2013;108:179-82.
19. Grantzau T, Thomsen MS, Vaeth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. *Radiother Oncol* 2014;111:366-73.
20. Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women treated for breast cancer. *J Natl Cancer Inst* 1994;86:983-8.
21. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. *Radiother Oncol* 2007;82:254-64.
22. Hurkmans CW, Cho BC, Damen E, Zijp L, Mijnheer BJ. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. *Radiother Oncol* 2002;62:163-71.
23. Liu H, Chen X, He Z, Li J. Evaluation of 3D-CRT, IMRT and VMAT radiotherapy plans for left breast cancer based on clinical dosimetric study. *Comput Med Imaging Graph* 2016;54:1-5.
24. Goddu SM, Chaudhari S, Mamalui-Hunter M, et al. Helical tomotherapy planning for left-sided breast cancer patients with positive lymph nodes: comparison to conventional multiport breast technique. *Int J Radiat Oncol Biol Phys* 2009;73:1243-51.

25. Coon AB, Dickler A, Kirk MC, et al. Tomotherapy and Multifield Intensity-Modulated Radiotherapy Planning Reduce Cardiac Doses in Left-Sided Breast Cancer Patients with Unfavorable Cardiac Anatomy. *Int J Radiat Oncol Biol Phys* 2010;72:104-10.
26. Fogliata A, Clivio A, Nicolini G, Vanetti E, Cozzi L. A treatment planning study using non-coplanar static fields and coplanar arcs for whole breast radiotherapy of patients with concave geometry. *Radiother Oncol* 2007;85:346-54.
27. Beckham WA, Popescu CC, Patenaude VV, Wai ES, Olivetto IA. Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? *Int J Radiat Oncol Biol Phys* 2007;69:918-24.
28. Remouchamps VM, Vicini FA, Sharpe MB, Kestin LL, Martinez AA, Wong JW. Significant reductions in heart and lung doses using deep inspiration breath hold with active breathing control and intensity-modulated radiation therapy for patients treated with locoregional breast irradiation. *Int J Radiat Oncol Biol Phys* 2003;55:392-406.
29. Lauche O, Kirova YM, Fenoglietto P, et al. Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy. *World J Radiol* 2016;8:735-42.
30. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. *Lancet Oncol* 2013;14:1086-94.
31. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. *N Engl J Med* 2010;362:513-20.
32. Korreman SS, Pedersen AN, Nottrup TJ, Specht L, Nystrom H. Breathing adapted radiotherapy for breast cancer: comparison of free breathing gating with the breath-hold technique. *Radiother Oncol* 2005;76:311-8.
33. Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet* 2017. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. *Lancet* 2016;387:229-38.
35. Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. *Lancet Oncol* 2013;14:1269-77.
36. Marta GN, Macedo CR, Carvalho Hde A, Hanna SA, da Silva JL, Riera R. Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. *Radiother Oncol* 2015;114:42-9.
37. Offersen B. Partial breast radiotherapy after breast conservation for breast cancer: early results from the randomised DBCG PBI trial. *Radiother Oncol* 2017;124:S163.
38. Mulliez T, Veldeman L, van Greveling A, et al. Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial comparing prone and supine positions. *Radiother Oncol* 2013;108:203-8.
39. Veldeman L, Schiettecatte K, De Sutter C, et al. The 2-Year Cosmetic Outcome of a Randomized Trial Comparing Prone and Supine Whole-Breast Irradiation in Large-Breasted Women. *Int J Radiat Oncol Biol Phys* 2016;95:1210-7.
40. Osa EO, DeWyngaert K, Roses D, et al. Prone breast intensity modulated radiation therapy: 5-year results. *Int J Radiat Oncol Biol Phys* 2014;89:899-906.
41. Kirby AM, Evans PM, Donovan EM, Convery HM, Haviland JS, Yarnold JR. Prone versus supine positioning for whole and partial-breast radiotherapy: A comparison of non-target tissue dosimetry. *Radiother Oncol* 2010;96:178-84.
42. Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs supine positioning for breast cancer radiotherapy. *JAMA* 2012;308:861-3.
43. Lymberis SC, Dewyngaert JK, Parhar P, et al. Prospective Assessment of Optimal Individual Position (Prone Versus Supine) for Breast Radiotherapy: Volumetric and Dosimetric Correlations in 100 Patients. *Int J Radiat Oncol Biol Phys* 2012;84:902-9.
44. Mulliez T, Veldeman L, Speleers B, et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. *Radiother Oncol* 2015;114:79-84.

# LIST OF ABBREVIATIONS/ DEFINITIONS

---

**DIBH** = deep inspiration breath hold

*Technique used to reduce heart dose. Radiation is delivered while the patient holds her breath for a limited amount of time. In deep inspiration, the distance between the heart and the breast is increased.*

**3D CRT** = 3-dimensional conformal radiotherapy

*In 3D CRT, the shape of the beams is conform with the shape of the target volume, based on CT-images of the patient.*

**HT** = helical tomotherapy

*Technique of rotational IMRT or arc therapy with a 360° freedom of possible beam angles. HT uses a 6-MV accelerator mounted on a ring gantry that rotates around the patient while the table advances slowly through the bore as in a CT scan.*

**IMRT** = intensity modulated radiation therapy

*Type of 3D CRT in which the beams are subdivided in smaller beams of varying intensities to precisely irradiate the tumour. In breast radiotherapy the most common form of IMRT is based on 2 opposing beams, usually referred to as 'field-in-field IMRT'. For more complex targets, multiple beams are used, often referred to as 'full IMRT'. An alternative for full IMRT is VMAT or HT.*

**IORT** = intra-operative radiotherapy

*Technique which consists of treating the tumour bed in the operating room immediately after the breast-sparing procedure. Several technical solutions have been designed to achieve this goal. In Europe, a commonly used IORT technique is to treat the tumour bed with an intra-operative linear accelerator that produces high energy electrons*

**Multicatheter Interstitial Brachytherapy**

*In this approach multiple catheters are inserted through the tumour bed which are subsequently loaded with radio-active sources.*

**OAR** = organs at risk

**PBI** = partial breast irradiation

*A form of radiation delivered after breast conserving surgery limited to the part of the breast where the tumour was removed. Three main PBI techniques are used in clinical practice 1) **IMRT**, 2) **Multicatheter Interstitial Brachytherapy**, 3) **IORT** (intra-operative radiotherapy)*

**VMAT** = volumetric modulated arc therapy

*A form of rotational IMRT or arc therapy in which the gantry rotates around the patient, giving the advantage of 360° of possible beam angles.*

**WBI** = whole-breast irradiation



For more information, please visit our website:

**[www.bravo-radiotherapie.be](http://www.bravo-radiotherapie.be)**